Lansoprazole for children with poorly controlled asthma a randomized controlled trial

JAMA

Volumn 307, Issue 4, 2012, Pages 373-381

  Holbrook, Janet T ^a   Wise, Robert A ^b   Gold, Benjamin D ^c   Blake, Kathryn ^d   Brown, Ellen D ^a   Castro, Mario ^e   Dozor, Allen J ^f   Lima, John J ^g   Mastronarde, John G ^h   Sockrider, Marianna M ⁱ   Teague, W Gerald ^j  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Children's Center for Digestive Health Care   (United States)

^d NEMOURS CHILDREN S CLINIC   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f WESTCHESTER MEDICAL CENTER   (United States)

^g Nemour's Children's Clinic   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ TEXAS CHILDREN S HOSPITAL   (United States)

^j UNIVERSITY OF VIRGINIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LANSOPRAZOLE; PLACEBO; PREDNISONE;

ACUTE SINUSITIS; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; BRONCHITIS; CHILD; CONTROLLED STUDY; DISEASE CONTROL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ESOPHAGUS PH; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FRACTURE; GASTROESOPHAGEAL REFLUX; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; OTITIS MEDIA; PARALLEL DESIGN; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SCORING SYSTEM; SORE THROAT; UNITED STATES; UPPER RESPIRATORY TRACT INFECTION;

EID: 84856179016     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.2035     Document Type: Article

References (47)

1. Tucci F, Resti M, Fontana R, Novembre E, Lami CA, Vierucci A. Gastroesophageal reflux and bronchial asthma: prevalence and effect of cisapride therapy. J Pediatr Gastroenterol Nutr. 1993;17(3):265-270. (Pubitemid 23314059)
2. Cinquetti M, Micelli S, Voltolina C, Zoppi G. The pattern of gastroesophageal reflux in asthmatic children. J Asthma. 2002;39(2):135-142. (Pubitemid 34464571)
3. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition; European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition (NASPGHAN) and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2009;49(4):498-547.
4. Hancox RJ, Poulton R, Taylor DR, et al. Associations between respiratory symptoms, lung function and gastro-oesophageal reflux symptoms in a population-based birth cohort. Respir Res. 2006;7:142.
5. Andze GO, Brandt ML, St Vil D, Bensoussan AL, Blanchard H. Diagnosis and treatment of gastroesophageal reflux in 500 children with respiratory symptoms: the value of pH monitoring. J Pediatr Surg. 1991;26(3):295-299, discussion 299-300.
6. El-Serag HB, Gilger M, Kuebeler M, Rabeneck L. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology. 2001;121(6):1294-1299. (Pubitemid 33140446)
7. Harding SM, Richter JE. The role of gastroesophageal reflux in chronic cough and asthma. Chest. 1997; 111(5):1389-1402. (Pubitemid 27200101)
8. Sheikh S, Stephen T, Howell L, Eid N. Gastroesophageal reflux in infants with wheezing. Pediatr Pulmonol. 1999;28(3):181-186. (Pubitemid 29420283)
9. Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol. 2009;104 (5):1278-1295, quiz 1296.
10. Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH. Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy. J Med Econ. 2009;12(4):348-355.
11. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD:National Asthma Education and Prevention Program, National Heart, Lung, and Blood Institute; 2007. NIH publication 08-4051.
12. Kiljander TO, Harding SM, Field SK, et al. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2006;173(10):1091-1097. (Pubitemid 43726889)
13. Kiljander TO, Junghard O, Beckman O, Lind T. Effect of esomeprazole 40 mg once or twice daily on asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2010;181(10):1042-1048.
14. Mastronarde JG, Anthonisen NR, Castro M, et al American Lung Association Asthma Clinical Research Centers. Efficacy of esomeprazole for treatment of poorly controlled asthma. N Engl J Med. 2009; 360(15):1487-1499.
15. Khoshoo V, Haydel R Jr. Effect of antireflux treatment on asthma exacerbations in nonatopic children. J Pediatr Gastroenterol Nutr. 2007;44(3):331-335. (Pubitemid 46673380)
16. Juniper EF, Gruffydd-Jones K, Ward S, Svensson K. Asthma Control Questionnaire in children: validation, measurement properties, interpretation. Eur Respir J. 2010;36(6):1410-1416.
17. Juniper EF, Bousquet J, Abetz L, Bateman ED; GOAL Committee. Identifying "well-controlled" and "not well-controlled" asthma using the Asthma Control Questionnaire. Respir Med. 2006;100(4):616-621. (Pubitemid 43285748)
18. Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society Statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009; 180(1):59-99.
19. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest. 1998;114(4):998-1007. (Pubitemid 28495893)
20. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004; 113(1):59-65. (Pubitemid 38096162)
21. Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007; 119(4):817-825. (Pubitemid 46527825)
22. Schatz M, Kosinski M, Yarlas AS,Hanlon J, Watson ME, Jhingran P. The minimally important difference of the Asthma Control Test. J Allergy Clin Immunol. 2009;124(4):719-723, e1.
23. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res. 1996;5(1):35-46. (Pubitemid 26100501)
24. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in the parents of children with asthma. Qual Life Res. 1996; 5(1):27-34. (Pubitemid 26100500)
25. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing - 1999. Am J Respir Crit Care Med. 2000; 161(1):309-329. (Pubitemid 30055941)
26. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999; 159(1):179-187. (Pubitemid 29036522)
27. Deal L, Gold BD, Gremse DA, et al. Age-specific questionnaires distinguish GERD symptom frequency and severity in infants and young children: development and initial validation. J Pediatr Gastroenterol Nutr. 2005;41(2):178-185. (Pubitemid 41099365)
28. US Food and Drug Administration. FDA drug safety communication: possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsand-Providers/ucm213206.htm. Accessed October 5, 2011.
29. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986; 42(1):121-130.
30. Keene ON, Jones MR, Lane PW, Anderson J. Analysis of exacerbation rates in asthma and chronic obstructive pulmonary disease: example from the TRISTAN study. Pharm Stat. 2007;6(2):89-97. (Pubitemid 46938845)
31. Tolia V, Ferry G, Gunasekaran T, Huang B, Keith R, Book L. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr. 2002;35(suppl 4):S308-S318. (Pubitemid 35416901)
32. Khoshoo V, Mohnot S, Haydel R Jr, Saturno E, Edell D, Kobernick A. Bronchial hyperreactivity in nonatopic children with asthma and reflux: effect of antireflux treatment. Pediatr Pulmonol. 2009;44(11): 1070-1074.
33. Størdal K, Johannesdottir GB, Bentsen BS, et al. Acid suppression does not change respiratory symptoms in children with asthma and gastrooesophageal reflux disease. Arch Dis Child. 2005; 90(9):956-960. (Pubitemid 41232350)
34. Tolia V, Vandenplas Y. Systematic review: the extra-oesophageal symptoms of gastro-oesophageal reflux disease in children. Aliment Pharmacol Ther. 2009; 29(3):258-272.
35. Blondeau K, Mertens V, Dupont L, et al. The relationship between gastroesophageal reflux and cough in children with chronic unexplained cough using combined impedance-pH-manometry recordings. Pediatr Pulmonol. 2010;46:286-294.
36. Di Mango E, Holbrook JT, Simpson E, et al American Lung Association Asthma Clinical Research Centers. Effects of asymptomatic proximal and distal gastroesophageal reflux on asthma severity. Am J Respir Crit Care Med. 2009;180(9):809-816.
37. Orenstein SR, Hassall E, Furmaga-Jablonska W, Atkinson S, Raanan M. Multicenter, double-blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr. 2009;154(4):514-520, e4.
38. Meijvis SC, Cornips MC, Voorn GP, et al. Microbial evaluation of proton-pump inhibitors and the risk of pneumonia. Eur Respir J. 2011;38(5):1165-1172.
39. Eom CS, Jeon CY, Lim JW, Cho EG, Park SM, Lee KS. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011;183(3):310-319.
40. Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955-1960. (Pubitemid 39411203)
41. Canani RB, Cirillo P, Roggero P, et al Working Group on Intestinal Infections of the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics. 2006;117(5):e817-e820. (Pubitemid 46071346)
42. Ohara T, Arakawa T. Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells. Dig Dis Sci. 1999;44(8):1710-1715. (Pubitemid 29434749)
43. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors - inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14(suppl 1):74-81. (Pubitemid 30199109)
44. Zedtwitz-Liebenstein K, Wenisch C, Patruta S, Parschalk B, Daxböck F, Graninger W. Omeprazole treatment diminishes intra- and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118-1122. (Pubitemid 34508037)
45. Taylor AM. Pediatric focused safety review: proton pump inhibitors: esomeprazole, lansoprazole, omeprazole, rabeprazole. June 21, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM216303.pdf. Accessed October 5, 2011.
46. US Food and Drug Administration. Transcripts of the June 21, 2010, meeting of the Pediatric Advisory Committee. June 21, 2010. http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ PediatricAdvisoryCommittee/UCM219336.pdf. Accessed October 5, 2011.
47. US Food and Drug Administration. Transcripts of the November 5, 2010, meeting of the Gastrointestinal Drugs Advisory Committee. November 5, 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/ Drugs/GastrointestinalDrugsAdvisoryCommittee/UCM237495.pdf. Accessed October 5, 2011.